Solid Biosciences Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Solid Biosciences Inc. (SLDB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $59.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19
- Solid Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $59.75M, a 53.26% increase from fiscal 2024.
- Solid Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $38.98M.
- Solid Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$71.86M, a 305.34% decline from fiscal 2022.
- Solid Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $35.00M, a 25.75% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $59.75M 10-K · filed 2026-03-19 |
| 2024-12-31 | $38.98M 10-K · filed 2026-03-19 |
| 2023-12-31 | -$71.86M 10-K · filed 2025-03-06 |
| 2022-12-31 | $35.00M 10-K · filed 2024-03-13 |
| 2021-12-31 | $27.83M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |